Stocktoria
Decoy Therapeutics Inc. DCOY
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-01-29
Decoy Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $1.8M |
| R&D expense | $368,170 | $770,027 | $7.2M | $15.8M | $8.5M |
| Operating income | -$12.6M | -$5.7M | -$12.9M | -$31.8M | -$12.8M |
| Income tax | $0 | — | — | — | — |
| Net income | -$12.5M | -$5.6M | -$12.5M | -$31.6M | -$12.8M |
| EPS (diluted) | $-129.10 | $-69.54 | $-30.74 | $-14.88 | $-7.72 |
| Operating cash flow | -$4.8M | -$4.5M | -$12.8M | -$17.6M | -$10.2M |
| Free cash flow | — | — | — | — | -$10.2M |
| Cash & equivalents | $10.7M | $2.4M | $5.9M | $12.1M | $29.2M |
| Total assets | $11.1M | $3.0M | $6.6M | $14.7M | $40.8M |
| Total liabilities | $5.2M | $1.5M | $1.3M | $4.3M | $2.1M |
| Shareholders' equity | $5.9M | $1.5M | $5.3M | $10.4M | $38.7M |
Source: SEC EDGAR filings · CIK 0001615219 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.